Clinuvel hopes to shine as photoprotective nears market
This article was originally published in Scrip
Executive Summary
Clinuvel's only product, afamelanotide, will be ready to launch in Europe by the end of next year, and the company is still on track to become a billion-dollar firm, its CEO Dr Philippe Wolgen told Scrip.